BR112020008936A2 - análogos e pepticorpos de glp-2 para administração antes, durante ou após a cirurgia - Google Patents

análogos e pepticorpos de glp-2 para administração antes, durante ou após a cirurgia Download PDF

Info

Publication number
BR112020008936A2
BR112020008936A2 BR112020008936-2A BR112020008936A BR112020008936A2 BR 112020008936 A2 BR112020008936 A2 BR 112020008936A2 BR 112020008936 A BR112020008936 A BR 112020008936A BR 112020008936 A2 BR112020008936 A2 BR 112020008936A2
Authority
BR
Brazil
Prior art keywords
glp
patient
surgery
peptibody
bowel syndrome
Prior art date
Application number
BR112020008936-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Clark Pan
Angela Norton
Bettina Strack-Logue
Clément Olivier
Original Assignee
Shire-Nps Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire-Nps Pharmaceuticals, Inc. filed Critical Shire-Nps Pharmaceuticals, Inc.
Publication of BR112020008936A2 publication Critical patent/BR112020008936A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112020008936-2A 2017-11-06 2018-11-05 análogos e pepticorpos de glp-2 para administração antes, durante ou após a cirurgia BR112020008936A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582055P 2017-11-06 2017-11-06
US62/582,055 2017-11-06
PCT/US2018/059175 WO2019090209A1 (en) 2017-11-06 2018-11-05 Glp-2 analogs and peptibodies for administration before during, or after surgery

Publications (1)

Publication Number Publication Date
BR112020008936A2 true BR112020008936A2 (pt) 2020-10-20

Family

ID=66332372

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020008936-2A BR112020008936A2 (pt) 2017-11-06 2018-11-05 análogos e pepticorpos de glp-2 para administração antes, durante ou após a cirurgia

Country Status (14)

Country Link
US (1) US11660328B2 (cg-RX-API-DMAC7.html)
EP (1) EP3706774A4 (cg-RX-API-DMAC7.html)
JP (2) JP7296958B2 (cg-RX-API-DMAC7.html)
KR (1) KR102825098B1 (cg-RX-API-DMAC7.html)
CN (1) CN111629745A (cg-RX-API-DMAC7.html)
AR (1) AR113835A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018360744A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020008936A2 (cg-RX-API-DMAC7.html)
CA (1) CA3079523A1 (cg-RX-API-DMAC7.html)
IL (1) IL274098B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004620A (cg-RX-API-DMAC7.html)
TW (1) TWI911137B (cg-RX-API-DMAC7.html)
WO (1) WO2019090209A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002080B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018321841A1 (en) * 2017-08-22 2020-02-20 Shire-Nps Pharmaceuticals, Inc. GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
WO2020086741A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
EP4126003A1 (en) * 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1809318T3 (da) * 2004-11-01 2013-09-08 Nps Pharma Inc Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
JP2009510999A (ja) * 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
AU2006321743A1 (en) * 2005-10-24 2007-06-14 Centocor, Inc. GLP-2 mimetibodies, polypeptides, compositions, methods and uses
US7812121B2 (en) * 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
JP2008247789A (ja) * 2007-03-30 2008-10-16 Kissei Pharmaceut Co Ltd クローン病に伴う腸管狭窄の進展抑制用医薬組成物
ES2687651T3 (es) * 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
US10137170B2 (en) * 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도

Also Published As

Publication number Publication date
IL274098B1 (en) 2024-08-01
US20210169986A1 (en) 2021-06-10
AR113835A1 (es) 2020-06-17
EP3706774A4 (en) 2021-09-08
TW201922279A (zh) 2019-06-16
KR20200085763A (ko) 2020-07-15
MX2020004620A (es) 2020-10-12
JP7296958B2 (ja) 2023-06-23
CA3079523A1 (en) 2019-05-09
TWI911137B (zh) 2026-01-11
RU2020118172A (ru) 2021-12-08
KR102825098B1 (ko) 2025-06-26
AU2018360744A1 (en) 2020-05-07
JP7752152B2 (ja) 2025-10-09
CN111629745A (zh) 2020-09-04
IL274098B2 (en) 2024-12-01
JP2023107883A (ja) 2023-08-03
US11660328B2 (en) 2023-05-30
ZA202002080B (en) 2025-11-26
JP2021502389A (ja) 2021-01-28
WO2019090209A1 (en) 2019-05-09
IL274098A (en) 2020-06-30
EP3706774A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
JP7752152B2 (ja) 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ
ES2733220T3 (es) Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento
ES2732291T3 (es) Péptidos terapéuticos
ES2278663T3 (es) Antagonistas del factor de crecimiento de celulas endoteliales vasculares vegf.
US8557769B2 (en) Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose
US7642241B2 (en) Methods of enhancing functioning of the large intestine
JP2009280598A (ja) 胃腸管上部の機能を強化する方法
JP2016540741A (ja) Gip−glp−1デュアルアゴニスト化合物及び方法
KR20110021758A (ko) 이형체-특이적 인슐린 유사체
US20090202494A1 (en) Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
JP6825181B2 (ja) 膵炎を治療するための薬剤の製造におけるil−22二量体の使用
BR112015010194B1 (pt) Análogo de insulina de cadeia única, sequência de ácido nucleico e uso do mesmo
JP2008518941A (ja) 大腸連続性を伴う短腸症候群患者の治療
ES2893813T3 (es) El tratamiento con GDF11 previene el aumento de peso, mejora la tolerancia a la glucosa y reduce la hepatoesteatosis
RU2795594C2 (ru) Пептитело glp-2 для введения до, в течение или после хирургического вмешательства
HK40037000A (en) Glp-2 analogs and peptibodies for administration before during, or after surgery
WO2024141054A1 (zh) 包含融合蛋白的药物组合物及其用途
WO2015057908A1 (en) Methods of treating diabetes and related disorders
HK1030160B (en) Methods of enhancing functioning of the upper gastrointestinal tract

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICALS U.S.A., INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]